A non-hallucinogenic version of the psychedelic drug ibogaine has been developed by David Olson and colleagues at the UC Davis Department of Chemistry. The new compound shows potential for treating psychiatric disorders including addiction in animal models and may work by increasing connectivity between nerve cells. Image of nerve cells by Lindsay Cameron, UC Davis
A non-hallucinogenic version of the psychedelic drug ibogaine, with potential for treating addiction, depression and other psychiatric disorders, has been developed by researchers at the University of California, Davis.
A paper describing the work is published Dec. 9 in Nature.
“Psychedelics are some of the most powerful drugs we know of that affect the brain,” said David Olson, assistant professor of chemistry at UC Davis and senior author on the paper. “It’s unbelievable how little we know about them.”
Ibogaine is extracted from the plant Tabernanthe iboga. There are anecdotal reports that it can have powerful anti-addiction effects such as reducing drug cravings and preventing relapse. But there are also serious side-effects, including hallucinations and cardiac toxicity, and the drug is a Schedule 1 controlled substance under U.S. law.
Olson’s laboratory at UC Davis is one of a few in the U.S. licensed to work with Schedule 1 substances. They set out to create a synthetic analog of ibogaine which retained therapeutic properties without the undesired effects of the psychedelic compound. Olson’s team worked through a series of similar compounds by swapping out parts of the ibogaine molecule. They engineered a new, synthetic molecule which they named tabernanthalog or TBG.
Models of anxiety, depression and addiction
Unlike ibogaine, the new molecule is water-soluble and can be synthesized in a single step. Experiments with cell cultures and zebrafish show that it is less toxic than ibogaine, which can cause heart attacks and has been responsible for several deaths.
TBG increased formation of new dendrites (branches) in rat nerve cells, and of new spines on those dendrites. That’s similar to the effect of drugs like ketamine, LSD, MDMA and DMT (the active component in the plant extract ayahuasca) on connections between nerve cells.
TBG did not, however, cause a head twitch response in mice, which is known to correlate with hallucinations in humans.
A series of experiments in rodent models of depression and addiction show that the new drug has promising positive effects. These animal models – conducted in accordance with NIH regulations and reviewed and approved by Institutional Animal Care and Use Committees – remain vital to investigating complex psychiatric disorders.
Mice trained to drink alcohol cut back their consumption after a single dose of TBG. Rats were trained to associate a light and tone with pressing a lever to get a dose of heroin. When the opiate is taken away, the rats develop signs of withdrawal and press the lever again when given the light and sound cues. Treating the rats with TBG had a long-lasting effect on opiate relapse.
Olson thinks that TBG works by changing the structure of neurons in key brain circuits involved in depression, anxiety, post-traumatic stress disorder and addiction.
“We’ve been focused on treating one psychiatric disease at a time, but we know that these illnesses overlap,” Olson said. “It might be possible to treat multiple diseases with the same drug.”
Indeed, psychedelic therapies have been attracting new interest in recent years. But taking patients on individual ‘trips’ is time consuming and costly, requiring hours of close medical supervision apart from the possible negative effects.
“We need a drug that people can keep in their medicine cabinet and this is a significant step in that direction,” Olson said.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- The Recovery Room: News beyond the pandemic — January 8on January 7, 2021 at 4:00 pm
The coronavirus pandemic has dominated the headlines and our daily lives for most of this year. Medical News Today have covered this fast-moving, complex story with live updates on the latest news ...
- Synthetic Psychedelic Treats Depression Without Hallucinationson January 5, 2021 at 9:42 am
Using a drug-designing method known as function-oriented synthesis, they were able to identify core aspects of how ibogaine works to recreate in a synthetic molecule called tabernanthalog (TBG). So ...
- Might a safer version of a psychedelic help treat depression?on January 4, 2021 at 12:07 pm
They then engineered these features into a new molecule: tabernanthalog (TBG). They derived the name from the Latin name for this group of plants, Tabernanthe iboga, meaning “tavern flower.” Unlike ...
- New Psychedelic Drug Could Treat Addiction and Depression, Without Hallucinationson December 17, 2020 at 3:37 am
They engineered a new, synthetic molecule which they named tabernanthalog or TBG. Models of anxiety, depression and addiction Unlike ibogaine, the new molecule is water-soluble and can be synthesized ...
- Progress Toward A Safer Psychedelic Drug To Treat Depression And Addictionon December 9, 2020 at 2:44 pm
The scientists named their creation tabernanthalog, or TBG. The team began testing TBG in rodents, including some mice raised to binge on alcohol. "Every single animal in the experiment reduced ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- MINDCURE Announces Pre- and Post-Psychedelic Therapy Adaptogen Supplements, Defining New Product Categoryon January 26, 2021 at 5:36 am
MINDCURE's proprietary line of integrative medicines, intended to balance the immune system and neurochemicals before and after psychedelic ...
- 4 Top Stocks for Huge Gains from the Psychedelic Renaissanceon January 25, 2021 at 10:15 pm
(GLOBE NEWSWIRE) -- OTC Stock Review was early to the party with an article on Seeking Alpha March 6, 2020 titled ” Psychedelic Medicine Stocks Capture the Attention of Investors .” Even though ...
- Ketamine to treat depression and addiction at UK’s first medical psychedelic psychotherapy clinicon January 25, 2021 at 10:57 am
The class B drug is to be used by Awakn Life Sciences when its centre opens in Bristol in March, explains its chief medical officer Dr Ben Sessa ...
- Military veteran seeks magic mushroom therapy to combat PTSDon January 24, 2021 at 11:48 am
Scott Atkinson says magic mushrooms have already done much to tame the post-traumatic stress demons conjured by two years serving in Afghanistan and Bosnia. But the retired Canadian Armed Forces ...
- Psychedelics as therapyon January 24, 2021 at 3:08 am
Research shows that hallucinogens can be highly effective treatments for anxiety, depression, addiction, and trauma ...